H3K27M-specific engineered immune effector (EIE) therapy (Geno-Immune Medical)

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameH3K27M-specific engineered immune effector (EIE) therapy (Geno-Immune Medical)
Drug Alias NameH3K27M-EIEs
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy
Mechanisms of Actionimmune cell agonist
TargetsNot applicable
Therapy Area/IndicationsDiffuse midline gliomaDiffuse Intrinsic Pontine Glioma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen Geno-Immune Medical Institute
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen Geno-Immune Medical Institute
Inactive CompaniesN/A
Active IndicationsDiffuse midline gliomaDiffuse Intrinsic Pontine Glioma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A